# US 8,277,820 B2 · Process for preparing variant of Erysipelothrix rhusiopathiae surface protective antigen in E. coli

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,820 B2
- Document ID: US8277820B2
- Status: Granted
- Kind: B2
- Application number: 10/590,896
- Filed: 2005-02-08
- Published: 2008-11-20
- Granted: 2012-10-02
- Earliest claimed: 2004-02-27
- Assignees: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
- Inventors: Toshihiro Ushijima; Masashi Sakaguchi; Eiji Tokunaga
- Web page: https://patentgrep.com/patent/US8277820B2

## CPC

- C07K 14/195: from bacteria
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A variant of Erysipelothrix rhusiopathiae surface protective antigen SpaA protein or of a shortened form of SpaA (ΔSpaA) in which a portion of SpaA protein is deleted for protection from Erysipelothrix rhusiopathiae infection and a process for preparing the same are provided. Introduction of amino acid substitution at a specific site in the amino acid sequence of SpaA or ΔSpaA protein provides a variant of SpaA or ΔSpaA protein which is immunogenic and is expressed in E. coli as inclusion bodies. The variant of SpaA or ΔSpaA protein of the present invention may easily be recovered and purified since it is expressed in E. coli as inclusion bodies.

## Claims

### Claim 1

An isolated variant of an Erysipelothrix rhusiopathiae surface protective antigen SpaA protein or of a shortened form thereof (known as ΔSpaA protein),
wherein the SpaA protein comprises the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO:7, and the ΔSpaA protein is a shortened form of the SpaA protein in which the C-terminal 206 amino acid residues of the SpaA protein comprising the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO:7 are deleted,
wherein said variant is immunogenic, and expressed in E. coli as inclusion bodies, and is selected from the group consisting of:
(1) the SpaA protein comprising the amino acid sequence encoded by SEQ ID NO:7 with the amino acid substitution of arginine to glycine at the residue corresponding to residue position 531 of SEQ ID NO:2;
(2) the SpaA protein comprising the amino acid sequence encoded by SEQ ID NO:7 with the amino acid substitution of histidine to glutamine at the residue corresponding to residue position 214 of SEQ ID NO:2 and the amino acid substitution of methionine to threonine at the residue corresponding to residue position 253 of SEQ ID NO:2;
(3) the ΔSpaA protein with the amino acid substitution of histidine to glutamine at the residue corresponding to residue position 214 of SEQ ID NO:2 and the amino acid substitution of methionine to threonine at the residue corresponding to residue position 253 of SEQ ID NO:2;
(4) the ΔSpaA protein with the amino acid substitution of glutamic acid to glycine at the residue corresponding to residue position 69 of SEQ ID NO:2, the amino acid substitution of glutamic acid to glycine at the residue corresponding to residue position 154 of SEQ ID NO:2, and the amino acid substitution of isoleucine to threonine at the residue corresponding to residue position 203 of SEQ ID NO:2; and
(5) the ΔSpaA protein with the amino acid substitution of aspartic acid to glycine at the residue corresponding to residue position 278 of SEQ ID NO:2.

### Claim 2

A composition comprising as an active ingredient an isolated variant of an Erysipelothrix rhusiopathiae surface protective antigen SpaA protein or of a shortened form thereof (known as ΔSpaA protein),
wherein the SpaA protein comprises the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO:7, and the ΔSpaA protein is a shortened form of the SpaA protein, in which the C-terminal 206 amino acid residues of the SpaA protein comprising the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO:7 are deleted,
wherein said variant is immunogenic, and expressed in E. coli as inclusion bodies, and is selected from the group consisting of:
(1) the SpaA protein comprising the amino acid sequence encoded by SEQ ID NO:7 with the amino acid substitution of arginine to glycine at the residue corresponding to residue position 531 of SEQ ID NO:2;
(2) the SpaA protein comprising the amino acid sequence encoded by SEQ ID NO:7 with the amino acid substitution of histidine to glutamine at the residue corresponding to residue position 214 of SEQ ID NO:2 and the amino acid substitution of methionine to threonine at the residue corresponding to residue position 253 of SEQ ID NO:2;
(3) the ΔSpaA protein with the amino acid substitution of histidine to glutamine at the residue corresponding to residue position 214 of SEQ ID NO:2 and the amino acid substitution of methionine to threonine at the residue corresponding to residue position 253 of SEQ ID NO:2;
(4) the ΔSpaA protein with the amino acid substitution of glutamic acid to glycine at the residue corresponding to residue position 69 of SEQ ID NO:2, the amino acid substitution of glutamic acid to glycine at the residue corresponding to residue position 154 of SEQ ID NO:2, and the amino acid substitution of isoleucine to threonine at the residue corresponding to residue position 203 of SEQ ID NO:2; and
(5) the ΔSpaA protein with the amino acid substitution of aspartic acid to glycine at the residue corresponding to residue position 278 of SEQ ID NO:2.

### Claim 3 (depends on 1)

A method for immunizing against infection with Erysipelothrix rhusiopathiae, comprising administering the variant of claim 1 to an animal in need of immunization.

### Claim 4 (depends on 1)

The isolated variant of claim 1, wherein the SpaA protein comprises the amino acid sequence encoded by SEQ ID NO:7 with the amino acid substitution of arginine to glycine at the residue corresponding to residue position 531 of SEQ ID NO:2.

### Claim 5 (depends on 1)

The isolated variant of claim 1, wherein the SpaA protein comprises the amino acid sequence encoded by SEQ ID NO:7 with the amino acid substitution of histidine to glutamine at the residue corresponding to residue position 214 of SEQ ID NO:2 and the amino acid substitution of methionine to threonine at the residue corresponding to residue position 253 of SEQ ID NO:2.

### Claim 6 (depends on 1)

The isolated variant of claim 1, which is the ΔSpaA protein with the amino acid substitution of histidine to glutamine at the residue corresponding to residue position 214 of SEQ ID NO:2 and the amino acid substitution of methionine to threonine at the residue corresponding to residue position 253 of SEQ ID NO:2.

### Claim 7 (depends on 1)

The isolated variant of claim 1, which is the ΔSpaA protein with the amino acid substitution of glutamic acid to glycine at the residue corresponding to residue position 69 of SEQ ID NO:2, the amino acid substitution of glutamic acid to glycine at the residue corresponding to residue position 154 of SEQ ID NO:2, and the amino acid substitution of isoleucine to threonine at the residue corresponding to residue position 203 of SEQ ID NO:2.

### Claim 8 (depends on 1)

The isolated variant of claim 1, which is the ΔSpaA protein with the amino acid substitution of aspartic acid to glycine at the residue corresponding to residue position 278 of SEQ ID NO:2.

### Claim 9 (depends on 2)

The composition of claim 2, wherein the SpaA protein comprises the amino acid sequence encoded by SEQ ID NO:7 with the amino acid substitution of arginine to glycine at the residue corresponding to residue position 531 of SEQ ID NO:2.

### Claim 10 (depends on 2)

The composition of claim 2, wherein the SpaA protein comprises the amino acid sequence encoded by SEQ ID NO:7 with the amino acid substitution of histidine to glutamine at the residue corresponding to residue position 214 of SEQ ID NO:2 and the amino acid substitution of methionine to threonine at the residue corresponding to residue position 253 of SEQ ID NO:2.

### Claim 11 (depends on 2)

The composition of claim 2, which is the ΔSpaA protein with the amino acid substitution of histidine to glutamine at the residue corresponding to residue position 214 of SEQ ID NO:2 and the amino acid substitution of methionine to threonine at the residue corresponding to residue position 253 of SEQ ID NO:2.

### Claim 12 (depends on 2)

The composition of claim 2, which is the ΔSpaA protein with the amino acid substitution of glutamic acid to glycine at the residue corresponding to residue position 69 of SEQ ID NO:2, the amino acid substitution of glutamic acid to glycine at the residue corresponding to residue position 154 of SEQ ID NO:2, and the amino acid substitution of isoleucine to threonine at the residue corresponding to residue position 203 of SEQ ID NO:2.

### Claim 13 (depends on 2)

The composition of claim 2, which is the ΔSpaA protein with the amino acid substitution of aspartic acid to glycine at the residue corresponding to residue position 278 of SEQ ID NO:2.
